1. Home
  2. FLX vs MLYS Comparison

FLX vs MLYS Comparison

Compare FLX & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • FLX
  • MLYS
  • Stock Information
  • Founded
  • FLX 2013
  • MLYS 2019
  • Country
  • FLX China
  • MLYS United States
  • Employees
  • FLX N/A
  • MLYS N/A
  • Industry
  • FLX
  • MLYS Biotechnology: Pharmaceutical Preparations
  • Sector
  • FLX
  • MLYS Health Care
  • Exchange
  • FLX NYSE
  • MLYS Nasdaq
  • Market Cap
  • FLX N/A
  • MLYS 1.0B
  • IPO Year
  • FLX 2024
  • MLYS 2023
  • Fundamental
  • Price
  • FLX $3.32
  • MLYS $14.80
  • Analyst Decision
  • FLX
  • MLYS Strong Buy
  • Analyst Count
  • FLX 0
  • MLYS 4
  • Target Price
  • FLX N/A
  • MLYS $27.00
  • AVG Volume (30 Days)
  • FLX 86.7K
  • MLYS 903.4K
  • Earning Date
  • FLX 08-27-2025
  • MLYS 08-12-2025
  • Dividend Yield
  • FLX N/A
  • MLYS N/A
  • EPS Growth
  • FLX N/A
  • MLYS N/A
  • EPS
  • FLX N/A
  • MLYS N/A
  • Revenue
  • FLX $595,490,250.00
  • MLYS N/A
  • Revenue This Year
  • FLX N/A
  • MLYS N/A
  • Revenue Next Year
  • FLX N/A
  • MLYS N/A
  • P/E Ratio
  • FLX N/A
  • MLYS N/A
  • Revenue Growth
  • FLX N/A
  • MLYS N/A
  • 52 Week Low
  • FLX $2.01
  • MLYS $8.24
  • 52 Week High
  • FLX $21.95
  • MLYS $18.38
  • Technical
  • Relative Strength Index (RSI)
  • FLX N/A
  • MLYS 53.41
  • Support Level
  • FLX N/A
  • MLYS $13.44
  • Resistance Level
  • FLX N/A
  • MLYS $14.70
  • Average True Range (ATR)
  • FLX 0.00
  • MLYS 0.67
  • MACD
  • FLX 0.00
  • MLYS 0.12
  • Stochastic Oscillator
  • FLX 0.00
  • MLYS 99.44

About MLYS Mineralys Therapeutics Inc.

Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.

Share on Social Networks: